VivoSeq
Other

Liposomal Doxorubicin

0

Pipeline Programs↗

3

Active Trials↗

6

Companies Involved↗

Liposomal Doxorubicin is an early-stage landscape with 0 programs across 6 companies. The most active players are Gynecologic Oncology Group, Sequus Pharmaceuticals, Bayer.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

79/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gynecologic Oncology Group

0 programs

PreclinicalS

Sequus Pharmaceuticals

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalCSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

0 programs

PreclinicalSanofi logo

Sanofi

0 programs

PreclinicalAbbVie logo

AbbVie

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

25

clinical trials

Completed15 · 60%
Terminated4 · 16%
Unknown status3 · 12%
Active, not recruiting1 · 4%
Not yet recruiting1 · 4%
Recruiting1 · 4%

Clinical Trials

Trial Activity

25 trials

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Recruiting·—·Phase 1·NCT05210374·24 enrolled
Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
Active, not recruiting·National Cancer Institute (NCI)·Phase 1·NCT02659930·62 enrolled
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
Not yet recruiting·AAIDS Malignancy Consortium·Phase 3·NCT05411237·130 enrolled
Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer
Completed·Bayer logoBayer·Phase 1·NCT02751918·65 enrolled
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Completed·GGynecologic Oncology Group·Phase 1·NCT01294293·20 enrolled
Multicenter Trial With PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
Completed·AAGO Study Group·Phase 2·NCT00815945·41 enrolled
Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00020449
Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001059·120 enrolled
Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere)
Completed·UUniversity of Southern California·Phase 1·NCT00183742·35 enrolled
Combination Chemotherapy Consisting of Pegylated Liposomal Doxorubicin and Carboplatin in Malignant Gynecologic Tumours
Completed·AAGO Study Group·Phase 2·NCT00189410·140 enrolled
Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT00923936·16 enrolled
Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
Completed·SSequus Pharmaceuticals·Phase 3·NCT00002105·220 enrolled
Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
Completed·SSequus Pharmaceuticals·Phase 3·NCT00002147
Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers
Completed·WWashington University School of Medicine·Phase 1·NCT00003207·14 enrolled
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02456857·17 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)